UroGen Pharma (NASDAQ:URGN) Price Target Raised to $40.00

UroGen Pharma (NASDAQ:URGNFree Report) had its target price upped by Oppenheimer from $32.00 to $40.00 in a report released on Friday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

Separately, HC Wainwright increased their price target on UroGen Pharma from $54.00 to $60.00 and gave the stock a buy rating in a report on Friday.

Read Our Latest Stock Analysis on UroGen Pharma

UroGen Pharma Trading Up 9.7 %

NASDAQ URGN opened at $19.20 on Friday. The stock’s 50 day moving average is $13.76 and its 200 day moving average is $15.05. UroGen Pharma has a 12 month low of $8.69 and a 12 month high of $24.13. The stock has a market cap of $450.32 million, a PE ratio of -5.65 and a beta of 1.08.

UroGen Pharma (NASDAQ:URGNGet Free Report) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.04). The company had revenue of $18.78 million for the quarter, compared to the consensus estimate of $20.73 million. On average, analysts forecast that UroGen Pharma will post -3.6 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Mark Schoenberg sold 5,153 shares of the business’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $13.08, for a total value of $67,401.24. Following the completion of the sale, the insider now owns 144,284 shares in the company, valued at approximately $1,887,234.72. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 11.13% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in URGN. RA Capital Management L.P. bought a new position in shares of UroGen Pharma during the 3rd quarter worth approximately $20,787,000. RTW Investments LP increased its position in shares of UroGen Pharma by 101.4% during the fourth quarter. RTW Investments LP now owns 1,726,808 shares of the company’s stock worth $25,902,000 after purchasing an additional 869,344 shares in the last quarter. Silverarc Capital Management LLC acquired a new position in shares of UroGen Pharma during the third quarter worth $7,129,000. Price T Rowe Associates Inc. MD purchased a new stake in shares of UroGen Pharma during the 1st quarter valued at $4,008,000. Finally, Superstring Capital Management LP acquired a new stake in shares of UroGen Pharma in the 4th quarter worth $3,831,000. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

About UroGen Pharma

(Get Free Report)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

Featured Stories

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.